Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01081808
Recruitment Status : Terminated (Funding ended)
First Posted : March 5, 2010
Last Update Posted : March 25, 2015
Information provided by (Responsible Party):
Roger Williams Medical Center

Brief Summary:

RATIONALE: Giving autologous lymphocytes that have been treated in the laboratory with antibodies may stimulate the immune system to kill tumor cells. Aldesleukin may stimulate the lymphocytes to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving laboratory-treated autologous lymphocytes together with aldesleukin and GM-CSF may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated autologous lymphocytes when given together with aldesleukin and GM-CSF in treating patients with recurrent, refractory, or metastatic advanced solid tumors.

Condition or disease Intervention/treatment Phase
Neoplasms Tumors Solid Tumors Metastatic Cancer Biological: EGFRBi-armed autologous activated T cells Phase 1

Detailed Description:



Determine the safety and maximum tolerated dose of EGFRBi-armed autologous activated T-cells (ATC) when administered in combination with low-dose aldesleukin and sargramostim (GM-CSF) in patients with recurrent, refractory, or extensive (metastatic) advanced solid tumors.


Assess clinical outcome based on tumor responses, overall survival, and progression-free survival.

Monitor changes in sera concentrations of the tumor-associated biomarkers respective of the primary neoplasm (i.e. carcinoembryonic antigen(CEA); prostate specific antigen (PSA); Her2/neu (HER2); etc.) in association with EGFRBi-armed ATC administration throughout the study and at time points thereafter.

Monitor patient sera for human anti-mouse antibodies (HAMA).

Evaluate immune response, which may reflect immune augmentation in response to EGFRBi-armed ATC infusions, in peripheral blood mononuclear cell (PBMC) samples as well as purified immune cell populations.

Investigate proliferation in response to ex vivo stimulation with tumor-specific antigens, sera cytokine profiles (Th1 vs Th2), cytotoxicity of patient PBMC, and interferon gamma ELISPOTS as a surrogate marker for assessing generation of EGFR-specific cytotoxic T-lymphocytes (CTL).

OUTLINE: Peripheral blood mononuclear cells (PBMCs) are collected by 1 or 2 leukaphereses for the generation of activated T cells (ATCs). The PBMCs are activated with OKT3 (anti-CD3) and expanded in aldesleukin for up to 14 days. The ATCs are then armed with EGFRBi.

Patients receive EGFRBi-armed autologous ATCs IV over 30-60 minutes twice weekly for 4 weeks (a total of 8 infusions) in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose aldesleukin subcutaneously (SC) once daily and sargramostim (GM-CSF) SC twice weekly beginning 3 days before the first ATC infusion and continuing for 1 week after the last ATC infusion.

After completion of study therapy, patients are followed periodically.

NOTE: For the purpose of determining safety and maximum tolerated dose of EGFRBi-armed ATC, patients enrolled at each dose level from this study will be combined with patients enrolled at each dose level in RWH 349-32 (NCT00569296): A phase I study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) to count toward each dose level cohort. A total of three patients enrolled form either of the two trials will be treated at each dose level, but at least one NSCLC patient representative from protocol 349-32 will be enrolled and evaluated at each dose level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors
Study Start Date : October 2009
Actual Primary Completion Date : December 2014
Actual Study Completion Date : February 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Aldesleukin

Arm Intervention/treatment
Armed Activated T Cells
Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
Biological: EGFRBi-armed autologous activated T cells
EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
Other Names:
  • ATC
  • IL-2
  • GM-CSF

Primary Outcome Measures :
  1. Maximum tolerated dose of EGFRBi-armed autologous activated T-cells [ Time Frame: 5 week regimen with 2 month follow up ]

Secondary Outcome Measures :
  1. Determine potential side effects of treating patients with Armed Activated T Cells (ATC) [ Time Frame: 5 week regimen with 2 month follow up ]
  2. Determination of immunologic changes by evaluation of cytokine profiles obtained before and after stimulation with OKT3 in vitro [ Time Frame: 5 week regimen with 2 month follow up ]
  3. Determination of immunologic changes by evaluation of phenotypes of peripheral blood mononuclear cells before and after immunotherapy [ Time Frame: 5 week regimen with 2 month follow up ]
  4. Overall survival [ Time Frame: 5 week regimen wtih 2 month follow up ]
  5. Progression-free survival [ Time Frame: 5 week regimen with 2 month follow up ]
  6. Determination of immunologic changes by evaluation of peripheral blood lymphocytes [ Time Frame: 5 week regimen with 2 month follow up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Histologically or cytologically confirmed solid tumor type (ex. Head and Neck Squamous Cell Carcinoma, Colorectal, Pancreatic, Gastric, Esophageal, Renal, Prostate, Breast and Ovarian cancers, etc.); high risk, recurrent, refractory, or metastatic disease after ≥ 1 prior first-line regimen (chemotherapy or radiotherapy)
  • Documented EGFR-positive disease (any expression level) by immunohistochemistry (IHC)
  • No clinical evidence of active brain metastases; patients with brain metastases are eligible provided they have received definitive radiotherapy or chemotherapy and/or have undergone surgical resection for brain metastases
  • No prior hematological malignancy
  • Karnofsky performance status (PS) 60-100% OR RCOG PS 0-2
  • Life expectancy ≥ 3 months
  • Not pregnant or nursing
  • Fertile patients must use contraception
  • Granulocytes ≥ 1,000/mm3
  • Platelet count ≥ 50,000/mm3
  • Hemoglobin ≥ 8g/dL
  • BUN ≤ 2.0 times normal
  • Serum creatinine ≤ 2.0mg/dL
  • Bilirubin ≤ 1.5 times normal (with or without liver metastases)
  • Hepatitis B surface antigen and HIV negative
  • LVEF ≥ 45% at rest by MUGA
  • No evidence of depressed left ventricular function
  • No other malignancy, except for the following:
  • History of curatively treated in situ squamous cell carcinoma or basal cell carinoma of the skin
  • History of other curatively treated malignancy (except those with a hematologic origin) for with the patient has remained in complete remission > 5 years after completing therapy (as documented by history, physical exams, tumor markers, and radiology scanning)

Exclusion Criteria

  • Serious medical or psychiatric illness that would preclude giving informed consent or receiving intensive treatment
  • Recent myocardial infarction (within the past year)
  • Current angina/coronary symptoms requiring medications
  • Clinical evidence of congestive heart failure requiring medical management (irrespective of MUGA results)
  • Systolic blood pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 m Hg; patients with elevated BP must have it controlled by anti-hypertensive medications for at least 7 days prior to the infusion
  • Clinical evidence of active brain metastases

Prior/Concurrent Therapy

  • More than 4 weeks since prior chemotherapy or radiotherapy
  • At least 4 weeks since prior cetuximab or small molecule EGFR-inhibitors including, but not limited to, gefitinib or erlotinib hydrochloride
  • No concurrent radiotherapy
  • No concurrent steroids except for treatment or adrenal failure, septic shock, or pulmonary toxicity or hormones for non-disease-related conditions(e.g., insulin for diabetes)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01081808

Layout table for location information
United States, Rhode Island
Roger Willaims Medical Center
Providence, Rhode Island, United States, 02908
Sponsors and Collaborators
Roger Williams Medical Center
Layout table for investigator information
Study Chair: Abby Maizel, MD,PhD Roger William Medical Center

Layout table for additonal information
Responsible Party: Roger Williams Medical Center Identifier: NCT01081808    
Other Study ID Numbers: RWH 111-32
First Posted: March 5, 2010    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: March 2015
Keywords provided by Roger Williams Medical Center:
Solid Tumor
T cell
Epidermal Growth Factor Receptor
Neoplasms by Site
Anti-Retroviral Agents
Therapeutic Uses
Anti-Infective Agents
Neoplasms by Histologic Type
Antineoplastic Agents
Antiviral Agents
Pharmacologic Actions
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents